Eosinophilic esophagitis (EoE), a chronic antigen-mediated disorder of children and adults, is diagnosed and monitored histologically, results in symptoms reflective of esophageal dysfunction, and does not currently have validated surrogate disease markers. 1, 2 One barrier to drug development and clinical trials in children is the lack of self-reported patient-reported outcome (PRO) metrics and the assumption that child report is unreliable and that parental report cannot serve as an adequate surrogate for a child's symptoms. 3 Because of these challenges, young children, often the population most in need of novel therapies to halt disease progression and/or alter natural history, are often excluded from clinical therapeutic trials. There are 2 EoE-specific validated outcome metrics for children and their parents, namely the Pediatric Eosinophilic Esophagitis Symptom Score, version 2.0 (PEESSv2.0), and the age-specific Pediatric QOL EoE module (PedsQL-EoE), version 3.0. [4] [5] [6] [7] [8] [9] [10] [11] However, it is currently not clear how well these outcome metrics perform in terms of an accurate reflection of the child's symptoms based on parental report. 5 In addition, it is not clear whether parent-reported or self-reported symptom and/or quality of life (QOL) metrics can perform as surrogate markers of tissue histology in children. 4, 12 The EoE Histology Scoring System (EoEHSS) is a validated module that reports the grade and stage of features of tissue damage and eosinophilia in the esophagus. 13 Eosinophil parameters include features of eosinophilic inflammation, eosinophil abscesses and surface layering, and surface epithelial alteration, as well as the architectural changes of basal zone hyperplasia, dilated intercellular spaces, dyskeratotic epithelial cells, and lamina propria fibrosis. The lack of validated indexes for symptoms/ QOL and histology was a prior barrier to completing a systematic assessment of PROs in relation to histology.
Use of multicenter consortia for rare diseases has a number of advantages over single-center studies including data obtained from multiple centers from across the United States and the ability to gather larger amounts of information in a shorter time period. The Consortium for Eosinophilic Gastrointestinal Disease Researchers (CEGIR) is a national collaborative network of 14 academic centers and patient advocacy groups caring for adults and children with eosinophilic gastrointestinal disorders.
14 The CEGIR clinical trial Outcomes Measures in Eosinophilic Gastrointestinal Disorders Across the Ages (OMEGA) is a longitudinal cohort study aimed at understanding the natural history of EoE, eosinophilic gastritis, and eosinophilic colitis during routine clinical care. 15 Using baseline PEESSv2.0 and PedsQL-EoE data generated from CEGIR subjects, we aimed to understand the alignment between parent-and child-reported symptoms and the correlation of symptoms with esophageal histology in a multicenter study.
METHODS PROs
Three hundred ten children aged 3 to 18 years and their parents completed the PEESSv2.0 child self-report, PEESSv2.0 parental proxy report, age-specific parental report, and/or self-report PedsQL-EoE questionnaires on entry into CEGIR OMEGA in 8 pediatric centers across the continental United States (ClinicalTrials.gov identification number NCT02523118). PedsQL-EoE self-report was used in children aged 5 to 18 years. PEESSv2.0 self-report was obtained from children aged 8 to 18 years. Parents of children aged 3 to 18 years completed the PEESSv2.0 parental report and age-specific PedsQL-EoE. Patients were consented/assented into the central (Cincinnati) and local institutional review board2 and National Institutes of Health2approved protocol.
The PEESSv2.0 is a content-validated metric for EoE-specific symptoms in children and assesses items within 4 domains: dysphagia, gastroesophageal reflux disease (GERD), nausea/vomiting, and pain. [4] [5] [6] PEESSv2.0 is scored from 0 to 100, with higher scores indicating more severe symptoms.
The PedsQL-EoE, version 3.0, is a content-validated index that measures the effect of various disease domains on QOL. PedsQL-EoE assesses the domains of symptoms I (chest pain, heartburn, stomach aches, vomiting, nausea, and food regurgitation), symptoms II (trouble swallowing, food stuck in the throat/chest, drinking to aid swallowing, and prolonged eating time), problems with treatment (difficulty with medications, doctor visits, endoscopies, and allergy testing), worry (regarding illness, doctor visits, endoscopies, and allergy testing), feelings, communication (parents, adults, friend, practitioners), and food/eating (difficulties with food elimination). 4, 8, 9 The PedsQL-EoE young child, child, and adolescent are self-reported metrics for children aged 5 to 7, 8 to 12, and 13 to 18 years old, respectively. The PedsQL-EoE for parents is a metric for parents of toddlers (2-4 years old), young children (5-7 years), children (8-12 years) , and adolescents (13-18 years) . It is scored from 0 to 100, with higher scores reflecting better QOL. Data were stored in the Data Management and Coordinating Center (DMCC) centralized database associated with the Rare Diseases Clinical Research Network (RDCRN) of the NIH.
Histologic evaluation
Whole slide images of esophageal biopsy specimens (3400 magnification) obtained within 630 days of PRO completion were reviewed by pathologists comprising the CEGIR pathology core (MHC, KEC, and G-YY). Pathologists were blinded to treatment status and therapy at the time the biopsy specimens were procured. Peak eosinophil counts were obtained, and the features of the EoEHSS were scored for both grade (severity) and stage (extent) and entered by the pathologists into the DMCC database. For the purposes of this analysis, EoEHSS features were grouped into those that relate directly to eosinophilic inflammation (ie, a score of peak eosinophil count, eosinophil abscesses, eosinophil surface layering, and surface epithelial alteration) and those that relate to architectural aspects (basal zone hyperplasia, dilated intercellular spaces, dyskeratotic epithelial cells, and lamina propria fibrosis). 13 
Statistics
Demographic and clinical characteristics of patients with EoE were summarized by using frequencies and percentages for categorical variables and medians (interquartile ranges [IQRs]) for continuous variables. Self-reports for PEESSv2.0 and PedsQL-EoE were matched to parental reports by date to assess correlation between these measures. Self-reports for PEESSv2.0 and PedsQLEoE also were matched by date for each participant. The same approach was used for parental reports. The earliest visit date that resulted in a match was used for each participant. PROs were matched with EoEHSS values within 630 days for associations between the metrics. The earliest endoscopy/HSS date that met the matching criteria was used for each patient in the analyses.
Missing data were most commonly due to the lack of an endoscopy done within 30 days of the PROs; the subjects were not required to have a new diagnosis or an accompanying endoscopy at the time of enrollment. Missing data also were a result of families not completing portions of a form or not completing forms in their entirety. For child self-report, not all age groups had PROs to fill out (<8 years old for PEESSv2.0 and < 5 years old for PedsQL-EoE).
Spearman nonparametric correlations (Spearman r values) are reported to assess the relationship between the following pairs of measurements: (1) parental versus child reports for PEESSv2.0 and PedsQL-EoE; (2) PEESSv2.0 versus PedsQL-EoE for self-reports and parental reports; and (3) EoEHSS versus PEESSv2.0 and PedsQL-EoE. For assessing associations between self-reports and parental reports and between PEESSv2.0 and PedsQL-EOE for self-report and parental report, Spearman correlations with P values of less than .001 were considered significant to control for multiple testing by using the Bonferroni adjustment and assuming a correlation of 0.5 among the end points tested. For correlation analyses of PROs with HSS, P values of less than .01 were considered significant to control for multiple testing by using the Bonferroni adjustment with a correlation of 0.5 among the end points tested. Data in the graphs also include P values of less than .05 to show trends.
Statistical analyses were done with SAS software (version 9.3; SAS, Cary, NC) and Sigmaplot version 13.0.
RESULTS

Baseline population
We analyzed cross-sectional data from 310 pediatric patients with EoE aged 3 to 18 years and recruited from 8 pediatric CEGIR centers. The mean 6 SD age was 10 6 4.1 years, 223 (73%) were male, and 262 (89%) were white, indicating that this population aligns with the reported demographics for the US population with EoE. Based on the presence of allergic rhinitis, food allergy, eczema, or aeroallergen/food-specific IgE, 189 (81%) of subjects were classified as atopic. At the time of their initial evaluation, more than 40% of subjects were receiving EoE-directed therapy with elimination diets, swallowed topical steroids, or both. Seven percent and 38% were receiving proton pump inhibitors alone or in combination with another therapy, respectively (Table I) .
Of the 310 children enrolled in CEGIR OMEGA, 254 (82%) and 290 (94%) had self-reported and parent-reported PedsQLEoE scores, respectively. One hundred eighty-four (59%) children had self-reported and 263 (85%) parents had usable baseline PEESSv2.0 metrics. Subjects were required to have at least 1 complete self-reported or parent-reported metric for inclusion in the analysis.
Baseline PedsQL-EoE and PEESSv2.0 scores in children and parents PedsQL-EoE. Self-reported PedsQL-EoE scores were reviewed from 70, 104, and 80 children aged 5 to 7 (young child), 8 to 12 (child), and 13 to 18 (adolescent) years old, respectively. The median highest self-reported QOL was in the communication domain, regardless of age: young child, 75 (IQR, 50-100); child, 85 (IQR, 60-100); and adolescent, 93 (IQR, 70-100). All child self-report groups had the poorest QOL in the domain of food and eating, with median scores of 50 (IQR, 25-63), 59 (IQR, 44-88), 63 (IQR, 38-88) in the young child, child, and adolescent groups, respectively. Overall, younger children tended to have poorer 
PPI, Proton pump inhibitor. *Atopy was defined as the presence of allergic rhinitis, eczema, or aeroallergen/foodspecific IgE.
QOL over multiple self-reported domains of PedsQL-EoE than did older children (Table II) . Parent-reported PedsQL-EoE scores were reviewed from 29, 72, 106, and 83 parents of toddler, young child, child, and adolescent subjects, respectively. Parental report for the best QOL domain varied by child's age, with high scores in multiple domains for children aged 5 to 7 years (median score range, 75-87.5), the communication domain for 8-to 12-year-olds (median score, 80 [IQR, 55-100]), and the symptoms I and symptoms II domains for 13-to 18-year-olds (median scores, 87.5 [IQR, 67-100] and 87.5 [IQR, 63-100]), respectively (Table II) .
PEESSv2.0. With the PEESSv2.0, children and their parents reported symptoms to be slightly more frequent rather than severe (Table III) . Children reported the highest median symptom frequency scores in the pain frequency domain (25 [IQR, ) and lowest symptom severity scores in the GERD and nausea/ vomiting severity domain (13 [IQR, 0-38]). In contrast, parents reported the highest symptom frequency scores for their children in the dysphagia frequency domain (30 [IQR, ).
Association between parent and child PROs: PedsQL-EoE and PEESSv2.0 Parent to age-specific PedsQL-EoE scores. To understand whether parental report associated with child self-report, we assessed the relationship between parent and child PROs by child age group. Matched parent age group PedsQL-EoE PROs were available from 64, 101, and 73 parents and children in the young child, child, and adolescent subject groups, respectively. PedsQLEoE gauges the effect on QOL in 7 domains. Symptoms I assesses pain, vomiting/nausea, and heartburn/regurgitation symptoms, whereas symptoms II assesses dysphagia symptoms. The remaining domains assess the effects of medications, testing, procedures, doctors' office visits (''treatment''), worry, communication about their disease (''communication''), restricted diets (''food/ eating''), and feelings about food restriction (''feelings'').
Parental reports and age-specific child self-reports of QOL correlated strongly over almost all domains in children up to 12 years old (Table II) . In the 5-to 7-year-old children, the domains of symptoms I, symptoms II, worry, communication, food/eating, and feelings correlated significantly (r 5 0.57-0.83, P < .001 for all) between parents and their children. In children 8 to 12 years old, the domains of symptoms I and II, treatment, worry, communication, food/eating, and feelings all correlated strongly and significantly (r 5 0.52-0.70, P < .001 for all) between children and their parents (Table II) . In the 13-to 18-year-old group, symptoms I and II and food/eating correlated the most strongly (r 5 0.54-0.62, P < .001 for all) between children and their parents (Table II) . These data suggest that parental and child QOL assessments align more strongly in children less than 13 years of age. Although symptom domains align tightly, other domains, such as communication, worry, food/eating, (Table III) Table III ). Within the dysphagia domain items, for which both parents and children reported the highest symptom scores (eats less and needs more time to eat), there were strong correlations (r 5 0.67, P < .001; Table III ). These data suggest that the parental report of symptoms, as assessed by using the PEESSv2.0, can effectively reflect the child's symptoms in all domains and support the hypothesis that parent-reported symptoms accurately reflect the child self-report.
Associations between PROs within groups
A number of statistically significant and revealing patterns existed on comparison of the PROs with one another. Comparison of parental PEESSv2.0 and PedsQL-EoE scores revealed that among the 4 overall PEESSv2.0 domains of GERD, nausea/ vomiting, pain, and dysphagia, there were significant inverse correlations to the PedsQL-EoE symptoms I and II domains for all of the age groups (Fig 1) . An inverse correlation would be expected in the presence of worse symptoms; higher PEESSv2.0 scores are reflective of a greater effect, and lower PedsQL-EoE scores represent lower QOL. For all of the age groups of the parental reports, the PEESSv2.0 dysphagia domain correlated most strongly and inversely with the symptoms II domain on PedsQL-EoE (r 5 20.80 to 20.88, P < .001 for all; Fig 1) . For the PedsQL-EoE symptoms I domain, which represents GERD and nausea/vomiting symptom effect, the PEESSv2.0 domains of nausea/vomiting or pain correlated most strongly (r 5 20.80 to 20.85, P < .001 for all) in parental reports (Fig 1) . In parents of toddlers, the PedsQL-EoE symptoms I domain correlated inversely most strongly with each of the 4 PEESSv2.0 domains (r 5 20.67 to 20.86, P < .001 for all). There were inverse correlations (P < .05) over several of the 7 domains queried in the parental PedsQL-EoE and the 4 domains queried in the PEESSv2.0 questionnaire, suggesting that a simple intake measure, such as PEESSv2.0, might accurately reflect the loss of QOL as perceived by parents, especially in children aged 5 to 18 years (Fig 1) .
Among child self-reported PEESSv2.0 and PedsQL-EoE scores, there were significant inverse correlations among the 4 PEESSv2.0 domains and the PedsQL-EoE symptoms I or II domains (r 5 20.67 to 20.86, P < .001; Fig 2) . Some of the lowest symptom correlations were in mismatched domains (PEESSv2.0 GERD and PedsQL-EoE symptoms II and PEESSv2.0 dysphagia and PedsQL-EoE symptoms I), whereas some of the strongest correlations were between appropriately matched symptom domains (PEESSv2.0 GERD and PedsQLEoE symptoms I and PEESSv2.0 dysphagia and PedsQL-EoE symptoms II; r 5 20.73 to 20.86, P < .001). These data support the notion that among all the domains, symptoms significantly influence self-reported pediatric QOL in patients with EoE.
Correlation of symptoms and QOL with EoEHSS scores
Whole slide images of esophageal biopsy specimens from 145 subjects were available for histopathology. The median maximum peak eosinophil count in the esophagus in the cohort was 16 (IQR, 2-33) per high-power field. The most severe histologic features were in the architectural features group of the proximal and distal esophagus, with median scores of 0.25 and 0.42 (of 1.0 possible) for proximal and distal grade and median scores of 0.25 and 0.42 (of 1.0) for proximal and distal stage, respectively (Table IV) .
PEESSv2.0 score correlations with peak eosinophil counts. We correlated self-reported PEESSv2.0 domains with peak eosinophil counts. The scores for ''all frequency'' questions and GERD frequency showed a weak correlation with peak eosinophil counts in the proximal esophagus (r 5 0.26-0.30, P < .05) but did not reach statistical significance after adjusting for multiple testing (Fig 3, A) . There were no significant correlations with distal eosinophil counts.
PEESSv2.0 self-report scores and correlations with EoEHSS features. PEESSv2.0 self-report (overall frequency/ severity, GERD frequency, and nausea/vomiting severity) scores correlated with grade or stage of the eosinophil features group of the EoEHSS (0.31-0.35; P < .01 for all; Fig 3, B and C) . Architectural changes in the proximal esophagus tended to correlate with the symptoms of overall severity and GERD frequency, and nausea/vomiting frequency scores correlated significantly with structural features (r 5 0.33, P < .01; Fig 3, D and E) . It was striking that proximal eosinophil and structural features, as opposed to distal features (data not shown), were correlated with symptoms. Unlike child self-reported PEESSv2.0 symptoms, parent-reported PEESSv2.0 symptoms did not well reflect tissue histology.
PedsQL-EoE score correlations with EoEHSS features. The symptoms I and symptoms II domains of the selfreported PedsQL-EoE among 13-to 18-year-olds had inverse correlations with proximal eosinophil features on EoEHSS (Table V) . In addition, proximal architectural feature scores tended to be correlated with the PedsQL-EoE symptom domain in 5-to 7-year-olds. Self-reported PedsQL-EoE scores for children 8 to 12 years old did not align with any EoEHSS domains.
Parental report in the PedsQL-EoE worry domain of toddlers had a trend toward correlations, largely in the distal esophagus for eosinophil features (r 5 20.40 to 20.65, P <.05 for all; Table V) . Parental report of communication on PedsQL-EoE significantly correlated with distal peak eosinophil counts, as well as eosinophil and structural features in the distal esophagus. These data suggest that symptoms can positively correlate and QOL can negatively correlate with proximal esophageal histology, as assessed by using the EoEHSS.
DISCUSSION
In this article we report the relationships between parentreported and self-reported pediatric PROs and correlations between PROs and a validated histologic scoring tool, the EoEHSS, in a large, multicenter study as part of the CEGIR network. 14, 15 Because these patients had varying disease activity, this cohort likely represents a ''real-life'' reflection of chronic EoE symptoms and histology, which is a strength of this study.
We report a number of novel observations. First, we showed that parent-reported and child-reported symptoms gauged on the PEESSv2.0 align strongly across all domains, confirming a prior small study. 5 This was true for symptom frequency and severity in the overall domains of nausea/vomiting, GERD, dysphagia, and pain, as well as for multiple items within each domain. This observation is particularly salient because it could alter the current design of acceptable PROs used for clinical therapeutic trials.
Second, we demonstrated that the reported effect of EoE on QOL as gauged in the age-specific PedsQL-EoE positively correlated between parents and their children. This was true especially in the younger population (5-12 years old) over symptoms, worry, communication, eating, and feelings.
Third, we found statistically significant correlations between proximal EoEHSS eosinophil and architectural features with PEESSv2.0 domains by child self-report but not by parental PEESSv2.0 report.
Fourth, we found that PEESSv2.0 and PedsQL-EoE scores correlate inversely to one another, especially in the symptoms domain. This is logical because higher symptom scores on the PEESSv2.0 should translate to poorer QOL, as reflected in lower PedsQL-EoE scores.
Fifth, we report that eosinophil and architectural features in the proximal esophagus correlated inversely with self-reported PedsQL-EoE symptom scores in 2 of the 3 age groups, suggesting positive correlation of histology with lower QOL. Furthermore, parent-reported QOL measures of symptoms and worry inversely correlated with esophageal pathology in toddlers, suggesting that in the youngest children more severe histology associated with poorer perceived life quality. These findings have a number of potential effects in the field because they begin to point to (1) the ability of surrogate reports to reflect a child's symptoms of EoE and (2) the possibility of symptoms to reflect histologic changes in EoE. It is notable that the EoEHSS score had greater alignment with symptoms than isolated peak eosinophil counts and that there were stronger relationships between symptoms and histology in the proximal rather than distal esophagus.
From a statistical standpoint, we have attempted to correct for multiple testing by setting the statistical threshold at a P value of less than .01, but it is notable that statistical trends (P < .05) were nearly all observed in the proximal esophagus rather than the distal esophagus (data not shown), suggesting that these trends might well be relevant. Because the correlation between histology and symptoms/QOL as reported by children and parents was relatively weak, this area requires additional study.
By definition, children are a vulnerable population who, at less than 8 years of age, do not have PROs that are acceptable self-reported outcomes for drug development trials. This is because of the dogma that caregiver-or practitioner-filtered symptom tools do not constitute an adequate surrogate marker for ''self-report.'' 3 However, in this large crosssectional cohort of children with active and inactive EoE, parents of children aged 8 to 18 years could accurately assess their children's symptoms. Parents of children as young as 5 years can adequately gauge their children's QOL. Therefore these data might provide reliable validated measures for pediatric EoE, in which parental and child report can be used as acceptable PROs and reduce barriers for drug approval in children. [16] [17] [18] [19] . Correlation between child self-reported PEESSv2.0 and PedsQL-EoE scores. Correlation coefficients (Spearman r) between PEESSv2.0 domains of GERD, nausea/vomiting (N/V), pain, and dysphagia and the 7 domains of PedsQL-EoE (symptoms I, symptoms II, treatment, worry, food/eating, feelings, and communication) as reported by children aged 8 to 12 (A) and 13 to 18 (B) years are shown. *P < .05 and **P < .001. Our population had relatively mild symptoms and relatively good QOL on PEESSv2.0 and PedsQL-EoE. These findings likely reflect 2 distinct processes. First, the enrollment of some patients who were in histologic remission likely had an effect on symptom metrics. Second, the use of coping skills acquired during the course of a chronic disease allows symptom control through behavior modifications. It is likely that symptoms and QOL might be quite different in a newly diagnosed population of J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 1 children with active disease before any intervention compared with those with a longer duration of diagnosis. Comparative and longitudinal studies will yield insights into the alterations and potential disconnections between symptoms, QOL, and histology. Such studies are best done by using the same validated scoring tools over time. Indeed, the design of the CEGIR OMEGA trial is to gauge longitudinal symptoms, QOL, and histology. 14 Our future efforts focused on understanding symptom and histologic shifts over time in patients with EoE will be essential measures for further understanding of this chronic disease.
PEESSv2.0 and PedsQL-EoE aligned inversely and significantly with one another across both parents and their children, suggesting that greater symptom scores on PEESSv2.0 are associated with poorer QOL. This was most notable in the symptom domains of the PedsQL-EoE. In addition, the symptom domain of the PedsQL-EoE had stronger correlations with histology than those of the PEESSv2.0. These findings suggest that future development of a hybrid symptom and QOL tool might be able to accurately reflect histologic changes in the esophagus of children. Because children less than 5 years old cannot well describe their symptoms, these could be assessed by using parental report on a scoring tool, such as the PedsQL-EoE toddler, which aligned strongly with histology over symptoms and worry domains.
Lastly, parent-reported PedsQL-EoE in the youngest and oldest age groups inversely correlated with distal histologic features. This might suggest that parental report versus self-report align with different histologic metrics. These findings need to be verified and validated longitudinally and in larger cohorts.
In conclusion, we report a number of practical findings that could affect pediatric EoE management and clinical trial design. Our data suggest that parental report can be considered an accurate surrogate marker for child self-reported symptoms and QOL. In terms of clinical practice, the use of a simple metric, such as PEESSv2.0, can accurately reflect both child and parental assessments, but it is unlikely that symptoms or QOL can substitute for histologic assessment. Symptoms reflecting proximal esophageal histology might shift the focus of EoE to an area of the esophagus that is less influenced by acid. These data provide important insights for the development of future tools that could decrease the need for repeated invasive procedures in children. In addition, it is likely that parental report is an adequate PRO for use in interventional trials in children.
